BIO-TECHNE Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
TECH$72.82-0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| | Quarter Ended | |||||
| · · September 30, | ||||||
| · · 2025 · · 2024 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: · · | ||||||
| Net earnings | | $38,185 | | $33,600 | ||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | | | ||||
| Depreciation and amortization | | 24,340 | | 28,137 | ||
| Deferred income taxes | | 5,275 | | (5,340) | ||
| Stock-based compensation expense | | 11,682 | | 10,184 | ||
| (Gain) Loss on equity method investment | | | (294) | | | (374) |
| (Gain) Loss on investments | | | (2,054) | | | — |
| Asset impairment restructuring | | | — | | | 6,039 |
| Leases, net | | (912) | | 445 | ||
| Recovery of assets held-for-sale | | | (6,789) | | | — |
| Other operating activity | | 1,001 | | 935 | ||
| Change in operating assets and operating liabilities, net of acquisition: | | | ||||
| Trade accounts and other receivables, net | | 22,392 | | 21,563 | ||
| Inventories | | (14,002) | | (2,805) | ||
| Prepaid expenses | | 380 | | (3,158) | ||
| Trade accounts payable, accrued expenses, contract liabilities, and other | | (2,115) | | (10,911) | ||
| Salaries, wages and related accruals | | (22,101) | | (8,246) | ||
| Income taxes payable | | (27,403) | | (6,180) | ||
| Net cash provided by (used in) operating activities | | 27,585 | | 63,889 | ||
| | | | | | | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | | ||||
| Proceeds from sale of available-for-sale investments | | — | | 1,085 | ||
| Additions to property and equipment | | (5,363) | | (9,172) | ||
| Distributions from Wilson Wolf | | | 1,351 | | | 1,403 |
| Investment in Spear Bio | | | — | | | (15,000) |
| Proceeds from sale of assets held-for-sale | | | 4,617 | | | — |
| Net cash provided by (used in) investing activities | | 605 | | (21,684) | ||
| | | | | | | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | | ||||
| Cash dividends | | (12,444) | | (12,688) | ||
| Proceeds from stock option exercises | | 23,495 | | 25,101 | ||
| Repurchases of common stock | | (24) | | — | ||
| Repayments of long-term debt | | (46,000) | | (19,000) | ||
| Taxes paid on RSUs and net share settlements | | | (9,231) | | | (4,984) |
| Net cash provided by (used in) financing activities | | (44,204) | | (11,571) | ||
| | | | | | | |
| Effect of exchange rate changes on cash and cash equivalents | | (1,210) | | 5,115 | ||
| Net change in cash and cash equivalents | | (17,224) | | 35,749 | ||
| Cash and cash equivalents at beginning of period | | 162,186 | | 151,791 | ||
| Cash and cash equivalents at end of period | | $144,962 | | $187,540 | ||
| | | | | | | |
| Supplemental disclosure of cash flow information: | | | | | | |
| Cash paid for income taxes | | $30,812 | | $16,490 | ||
| Cash paid for interest | | $4,822 | | $5,205 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.